US 7,030,135 B2 · Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1

Abstract

The present invention relates to using a compound having the formula (I) wherein T is I) thienyl, which optionally is substituted with halogen, or II) phenyl optionally substituted with halogen and/or C1-6-alkyl; E is a bond, —CH2— or —CO—; L is a bond, —CH2—, —CHR4— or —NR3—; R3 is H, C1-6-alkyl, C1-6-acyl or —COR4; R4 is morpholino or C1-6-amido; R6 and R7 are independently hydrogen or C1-6-alkyl; and R8 and R9 are independently hydrogen or C1-6-alkyl, as well as pharmaceutically acceptable salts, hydrates and solvates thereof, in the manufacture of a medicament for the treatment or prevention of diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, osteoporosis, tuberculosis, dementia, depression, virus diseases and inflammatory disorders.

Claims8

Dependent claims

A compound accordingly to the formula (I):

wherein
T is
I) thienyl, which optionally is substituted with at least one halogen or
II) phenyl substituted with
a) at least one of C2-6 alkyl;
or
b) at least one C1-6 alkyl and at least one halogen;
or
c) at least three halogens;
E is a bond, —CH2— or —CO—;
L is a bond, —CH2—, —CHR4 — or —NR3—;
R3 is H, C1-6 alkyl, C1-6 acyl or —COR4—;
R4 is morpholinyl or C1-6 amido;
R6 and R7 are independently hydrogen or C1-6 alkyl and
R8 and R9 are independently hydrogen or C1-6 alkyl, as well as pharmaceutically acceptable salts, hydrates and solvates thereof.

12 more elements

A method for the treatment of diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia or hyperinsulinemia, said method comprising administering to mammal, in need of such treatment, an effective amount of a compound having the formula (I):

wherein
T is
I) thienyl, which optionally is substituted with at least one halogen or
II) phenyl substituted with
a) at least one of C2-6 alkyl;
or
b) at least one C1-6 alkyl and at least one halogen;
or
c) at least three halogens;
E is a bond, —CH2— or 13 CO—;
L is a bond, —CH2—, —CHR4— or NR3—;
R3 is H, C1-6 alkyl, C1-6 acyl or COR4—;
R4 is morpholinyl or C1-6 amido;
R6 and R7 are independently hydrogen or C1-6 alkyl and
R8 and R9 are independently hydrogen or C1-6 alkyl, as well as pharmaceutically acceptable salts, hydrates and solvates thereof.

12 more elements

Dependencies are inferred from the claim text.

Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1

Life of this patent

Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1

Life of this patent

Abstract

Claims8